Sign Up for the Health Care Inc. Northwest Newsletter

Send this story to a friend

Nov 5, 2013, 6:40am PST

Omeros reports 'positive' eye drug results

Omeros reported "positive data" of a test of one of its eye drugs.

Contributing Editor- Puget Sound Business Journal
Email

Omeros Corp. shares were up in early Tuesday trading after the Seattle company announced "positive data" from the results of a test of its eye drug.

Omeros (NASDAQ: OMER) reported positive data of its "OMS721... in a ... model of neovascular age-related macular degeneration, which is characterized by abnormal growth of new blood vessels behind the retina of the eye and is a leading cause of vision loss in individuals over 60 years of age."

"The data from this study directly evaluating the activity of OMS721 ... further support its potential effects in the treatment of a wide range of complement-related diseases in humans," said Dr. Gregory Demopulos, chairman CEO of Omeros, in a statement.

Shares in Omeros were up more than 5 percent in early Tuesday trading, up 47 cents to $9.62.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Inside Puget Sound Business Journal

Where to Go Long in This Market?

Most Popular

  • Slideshows
  • Facebook
  • Twitter
  • Emailed
  • Mobile
Health Care Inc. Northwest brings you everything you need to know about health care in the Northwest.

Several retailers plan to open on Thanksgiving Day this year. Will you be among the early shoppers?


View Results
Post a Job

© 2013 American City Business Journals. All rights reserved. Use of this Site constitutes acceptance of our User Agreement (updated 3/14/12) and Privacy Policy (updated 3/14/12).

Your California Privacy Rights.

The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of American City Business Journals.

Ad Choices.